Core Scientific says capacity additions drive nearly 60% sequential Q3 colocation revenue growth
CORZ•Core Scientific said third-quarter 2026 colocation revenue rose nearly 60% sequentially to $215 million, while adjusted EBITDA increased to $134 million from $41 million. Liquidity fell about $1 billion to $1.7 billion, and management expects double-digit sequential revenue growth in the fourth quarter.
1. Q3 results and outlook
Core Scientific attributed its third-quarter gains to newly billable capacity and full-quarter contributions from earlier deliveries. Adjusted EBITDA rose to $134 million from $41 million in the second quarter, while liquidity declined approximately $1 billion to approximately $1.7 billion, reflecting capital expenditures primarily for AMD sites and the Polaris acquisition. Management expects double-digit sequential revenue growth in the fourth quarter as more capacity enters billing and earlier deliveries contribute for a full quarter.
